

Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease

(Supplement)

Fabian Maass, MD¹, Sebastian Rikker¹, Vivian Dambeck^{1,5,6}, Carmina Warth^{1,6}, Lars Tatenhorst, PhD^{1,3,5,6}, Ilona Csoti, MD², Matthias Schmitz^{1,3}, PhD, Inga Zerr, MD^{1,3}, Andreas Leha, PhD⁴, Mathias Bähr, MD^{1,5}, Paul Lingor, MD^{1,3,5,6,7}

¹ Department of Neurology, University Medical Center Göttingen, Germany

² Gertrudis Clinic Parkinson-Center, Biskirchen, Germany

³ DZNE, German Center for Neurodegenerative Diseases Göttingen, Germany

⁴ Department of Medical Statistics, University Medical Center, Göttingen, Germany

⁵ Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany

⁶ Center for Biostructural Imaging of Neurodegeneration (BIN), University Medical Center Göttingen, Germany

⁷ Department of Neurology, Rechts der Isar Hospital of the Technical University Munich, 80333 Munich, Germany

Corresponding author:

Dr. med. Fabian Maass

Department of Neurology, University Medical Center Göttingen,

Robert-Koch-Str. 40, DE-37075 Göttingen, Germany

Phone: + 049 551 39 8398

Email: fabian.maass@med.uni-goettingen.de

General characteristics of Simoa human α -synuclein assay

(as reported by the manufacturer)

Calibration range	0-1,000 pg/mL
Dynamic range	0-10,000 pg/mL
Lower limit of detection	0.955 pg/mL
Lower limit of quantification	4.12 pg/mL
Spike-recovery (serum/plasma)	86.0%
Spike-recovery (CSF)	105.7%
Dilution Linearity (serum)	94.7%
Dilution Linearity (CSF)	88.0%
Typical sample volume	19 μ l
Minimum sample volume	2.1 μ l

Precision characteristics of Simoa Human α -Synuclein immunoassay

(as reported by the manufacturer)

Sample	Mean αSynuclein (pg/mL)	Within Run %CV (n=5)	Between Run %CV (n=5)
Serum panel 1	1933.4	3.1	3.2
Serum panel 2	3325.0	5.2	2.2
Serum panel 3	563	3.1	2.3